Nasdaq · CIK 0001709941
BIOA BioAge Labs, Inc.
Insider trading from SEC Form 4. Last filing Aug 11, 2025. Close $6.34 on Oct 9, 2026, +24% from the 52-week low and -75% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
BIOAOct 9, 2026 · close 6.34
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at BioAge Labs, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 29Weak | Shane Barton Principal Accounting Officer buy | $47k 2,632 shares | - | - |
Transactions
The last 13 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 7, 2025 | Vijay Satyanand Pande director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Aug 11, 2025 |
| Jun 5, 2025 | Jean Pierre Garnier director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| Jun 5, 2025 | Michael H. Davidson director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| Jun 5, 2025 | Patrick G Enright director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| Jun 5, 2025 | James Healy director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| Jun 5, 2025 | Rekha Hemrajani director | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| Sep 27, 2024 | Shane Barton Principal Accounting Officer | POpen-market purchase Common Stock | +2,632 | $18.00 | $47k | 2,632 | Mar 10, 2025 |
| Feb 18, 2025 | Shane Barton Principal Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Feb 20, 2025 |
| Feb 18, 2025 | Kristen Fortney Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +530,000 | $0.00 | $0 | 530,000 | Feb 20, 2025 |
| Feb 18, 2025 | Dov A Goldstein Md Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +170,000 | $0.00 | $0 | 170,000 | Feb 20, 2025 |
| Feb 18, 2025 | Eric Morgen Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Feb 20, 2025 |
| Feb 18, 2025 | Paul D Rubin Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Feb 20, 2025 |
| Dec 18, 2024 | Shane Barton Principal Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Dec 20, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Shane BartonPrincipal Accounting Officer
- Michael H. Davidsonceo, officer, director
- Patrick G Enrightdirector
- Kristen FortneyChief Executive Officer
- Jean Pierre Garnierdirector
- Dov A Goldstein MdChief Financial Officer
- James Healydirector
- Rekha Hemrajanidirector
- Eric MorgenChief Operating Officer
- Vijay Satyanand Pandedirector
- Paul D RubinChief Medical Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.